The Primary Biliary Cholangitis Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Primary Biliary Cholangitis Market:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

According to The Business Research Company’s Primary Biliary Cholangitis Global Market Report 2024, The primary biliary cholangitis market size has grown rapidly in recent years. It will grow from $0.87 billion in 2023 to $0.98 billion in 2024 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increased disease awareness, rising global healthcare expenditure, strategic collaborations in the healthcare sector, focus on patient advocacy, government initiatives for liver health..

The primary biliary cholangitis market size is expected to see rapid growth in the next few years. It will grow to $1.46 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to expansion of biomarker research, global efforts in rare disease management, increased collaboration in clinical trials, patient-centric healthcare approaches, rising demand for liver transplants.. Major trends in the forecast period include advancements in biomarker research, growing emphasis on non-invasive diagnostic techniques, research focus on immunomodulatory therapies, integration of artificial intelligence (ai), patient-reported outcomes in clinical trials, telemedicine for patient management, focus on combination therapies, emerging therapies targeting fibrosis..

The increase in smoking is expected to propel the growth of the primary biliary cholangitis market going forward. Smoking refers to the act of inhaling and exhaling the smoke produced by burning tobacco or other substances. Smoking is a known risk factor for liver diseases, including PBC, and higher smoking rates can lead to more individuals seeking medical attention for liver-related issues. For instance, in July 2023, according to Statistics Canada, a Canada-based government agency, cigarette production increased by 2.2% compared to June 2023 in Canada. Moreover, there was a 2.6% rise in cigarette sales in June, reaching 1.4 billion units compared to May. Therefore, the increase in smoking will drive the growth of the primary biliary cholangitis market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Companies operating in the primary biliary cholangitis market are focused on developing innovative and specialized treatments, such as orphan drugs with a combination of obeticholic acid (OCA) and bezafibrates to treat primary biliary cholangitis (PBC), to gain market exclusivity. The combination of OCA and bezafibrate with an orphan drug designation aims to offer a more comprehensive and effective approach to managing PBC treatment, potentially improving the quality of life for individuals affected by this rare condition. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, received orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a potential treatment for primary biliary cholangitis (PBC), a progressive liver disease, and obeticholic acid (marketed as Ocaliva) is approved for PBC in the US.

The primary biliary cholangitis market report table of contents includes:



Executive Summary
Primary Biliary Cholangitis Market Characteristics
Primary Biliary Cholangitis Market Trends And Strategies
Primary Biliary Cholangitis Market - Macro Economic Scenario
Global Primary Biliary Cholangitis Market Size and Growth
.

.

.

Global Primary Biliary Cholangitis Market Competitive Benchmarking
Global Primary Biliary Cholangitis Market Competitive Dashboard
Key Mergers And Acquisitions In The Primary Biliary Cholangitis Market
Primary Biliary Cholangitis Market Future Outlook and Potential Analysis
Appendix
Top Major Players:

Pfizer Inc.
Hoffmann-La Roche Ltd
Novartis AG
Bristol-Myers Squibb Company
AstraZeneca PLC
Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]



Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model